Company: SHPH
Filing Date: 2025-02-13
Form Type: S-1
Source: 0001493152-25-006202
Chunk: 146

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-02-13
Form: S-1
Chunk 146
---
 installments over a one year period.

InOctober 2024, the Company conducted an up to $1.3 million 5% Original Issue Discount senior secured convertible note warrant offering (the “October 2024 Bridge Offering”), pursuant to which the Company issued a total of $831,579 in notes and warrants to purchase 329,461 shares of common stock, exercisable at a weighted-average exercise price of $1.42 per share. The notes bear interest at the rate of 14.5% per annum, with the interest payable quarterly in cash, mature one year after the date of issuance, are redeemable at any time by the Company at a 107% premium to the principal value of the notes and, three months after issuance, can be converted at any time by the holder at a 110% premium to the principal value of the note. The Company’s CEO purchased $250,000 of notes and warrants in the October 2024 Bridge Offering.

Review, Approval and Ratification of Related Party Transactions

All related party transactions are subject to the review, approval, or ratification of our board of directors or an appropriate committee thereof.

<div align='center'>CAPITALIZATION</div>

The following table sets forth our cash and cash equivalents and capitalization as of September 30, 2024:

| ● | on                                                                                                                                         
 an actual basis;                                                                                                                           |
| ● | on                                                                                                                                         
 a pro forma basis to reflect (i) the $790,000 in convertible bridge notes to related parties (including $250,000 to                        
 Dr. Dritschilo) in October, 2024, excluding proceeds from any exercise of 329,460 warrants issued in conjunction with                      
 the Convertible Bridge Notes; and (ii) the October 2024 public offering sale                                                               
 and issuance of 395,574 shares of common stock, 2,555,246 Pre-Funded Warrants and 2,950,820 Common Warrants at the combined offering price 
 of $1.525 per share of Common Stock (or less $0.001 per Pre-Funded Warrant) and one accompanying Common Warrant, resulting in net proceeds 
 of $4.0 million, after deducting approximately $405,000 in placement agent fees and other expenses.                                        |
| ● | on a pro forma as adjusted basis to                                                                                                        
 reflect the sale of [*] shares of common stock, or Pre-Funded Warrants in lieu                                                             
 thereof, in this offering at an assumed offering price of